Sacituzumab govitecan - Immunomedics
Alternative Names: GS-0132; hRS7-SN38 antibody drug conjugate; IMMU-132; IMMU0132; Isactuzumab govitecan; Sacituzumab govitecan-hziy; TRODELVY; Trodelvy; TROP-2-SN-38Latest Information Update: 16 Jul 2024
At a glance
- Originator Gilead Sciences; IBC Pharmaceuticals; Immunomedics; UNICANCER
- Developer Clovis Oncology; Gilead Sciences; Immunomedics; M. D. Anderson Cancer Center; Merck Sharp & Dohme; Pfizer; UNICANCER; University of Wisconsin Comprehensive Cancer Center; Yale University
- Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Indolizines; Monoclonal antibodies; Pyrans; Quinolines
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Triple negative breast cancer; Urogenital cancer
- Registered HER2 negative breast cancer
- Phase III Non-small cell lung cancer; Solid tumours
- Phase II Bladder cancer; Cervical cancer; Endometrial cancer; Prostate cancer
- Phase I/II Cancer
- No development reported Glioblastoma
Most Recent Events
- 03 Jul 2024 Gilead Sciences plans a phase III ASCENT-GYN-01 trial for Endometrial Cancer (Recurrent, Second-line therapy or greater) in September 2024 (IV) (NCT06486441, GS-US-682-6769)
- 02 Jun 2024 Updated adverse events data from the phase III EVOKE-01 trial in Non-small cell lung cancer released by Gilead Sciences
- 31 May 2024 Efficacy and adverse events data from a phase II trial in Non small cell lung cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)